David Calhoun to Hypertension
This is a "connection" page, showing publications David Calhoun has written about Hypertension.
Connection Strength
36.214
-
Matanes F, Siddiqui M, Velasco A, Sharifov O, Kreps E, Dudenbostel T, Judd EK, Zhang B, Lloyd SG, Oparil S, Calhoun DA. Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension. J Clin Hypertens (Greenwich). 2023 05; 25(5):416-425.
Score: 0.552
-
Dudenbostel T, Li P, Calhoun DA. Paradoxical Increase of 24-Hour Urinary Aldosterone Levels in Obese Patients With Resistant Hypertension on a High Salt Diet. Am J Hypertens. 2021 06 22; 34(6):600-608.
Score: 0.488
-
Thomas SJ, Siddiqui M, Judd E, Moore D, Harding SM, Oparil S, Calhoun D. Obstructive sleep apnea is more severe in men but not women with refractory hypertension compared with controlled resistant hypertension. J Hypertens. 2021 02 01; 39(2):286-291.
Score: 0.475
-
Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. Am J Hypertens. 2020 08 04; 33(8):741-747.
Score: 0.459
-
Cai A, Siddiqui M, Judd EK, Oparil S, Calhoun DA. Aortic blood pressure and arterial stiffness in patients with controlled resistant and non-resistant hypertension. J Clin Hypertens (Greenwich). 2020 02; 22(2):167-173.
Score: 0.444
-
Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension. 2020 02; 75(2):510-515.
Score: 0.439
-
Flack JM, Calhoun D. The ACC/AHA and ESC/ESH Hypertension Guidelines: Contrasting Versions of Idiosyncratic Excellence. Am J Hypertens. 2019 07 17; 32(8):705-708.
Score: 0.427
-
Calhoun DA. The Year in Clinical Hypertension From Other Pages. Am J Hypertens. 2019 04 22; 32(5):441-444.
Score: 0.420
-
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019 03 29; 124(7):1061-1070.
Score: 0.418
-
Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Am J Hypertens. 2019 01 01; 32(1):1-3.
Score: 0.411
-
Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG, Oparil S, Calhoun DA. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018 08; 72(2):343-349.
Score: 0.395
-
Siddiqui M, Phillips RA, Bursztyn M, Sica D, Velasco A, Judd EK, Dudenbostel T, Lloyd SG, Oparil S, Calhoun DA. Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. Hypertension. 2018 07; 72(1):3-9.
Score: 0.393
-
Cai A, Calhoun DA. Antihypertensive Medications and Falls in the Elderly. Am J Hypertens. 2018 02 09; 31(3):281-283.
Score: 0.386
-
Calhoun DA, Grassi G. True versus pseudoresistant hypertension. J Hypertens. 2017 12; 35(12):2367-2368.
Score: 0.381
-
Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. Hypertension. 2017 09; 70(3):645-651.
Score: 0.371
-
Calhoun DA. Sleep disorders and hypertension risk. J Hum Hypertens. 2017 06; 31(6):371-372.
Score: 0.368
-
Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017 07; 70(1):5-9.
Score: 0.367
-
Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. Am J Hypertens. 2017 May 01; 30(5):518-523.
Score: 0.366
-
Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017 01; 26(1):14-19.
Score: 0.358
-
Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017 02; 11(2):122-129.
Score: 0.358
-
Dudenbostel T, Calhoun DA. Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. Am J Hypertens. 2017 01; 30(1):12-15.
Score: 0.355
-
Biaggioni I, Calhoun DA. Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep. Hypertension. 2016 12; 68(6):1338-1339.
Score: 0.352
-
Calhoun DA. Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. J Hypertens. 2016 09; 34(9):1701-3.
Score: 0.350
-
Calhoun DA. Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension. Circulation. 2016 09 20; 134(12):858-60.
Score: 0.350
-
Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. 2016 10; 68(4):995-1003.
Score: 0.349
-
Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016 May; 34(5):1005-10.
Score: 0.342
-
Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016 06; 67(6):1085-92.
Score: 0.341
-
Pimenta E, Calhoun DA. Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension? Curr Hypertens Rep. 2016 Apr; 18(4):25.
Score: 0.340
-
Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016 06; 10(6):493-9.
Score: 0.340
-
Judd E, Calhoun DA. Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk. Hypertension. 2016 Feb; 67(2):275-7.
Score: 0.334
-
Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. Can J Cardiol. 2016 05; 32(5):603-6.
Score: 0.323
-
Calhoun DA. Editorial comment: change in leadership. J Hum Hypertens. 2015 Jun; 29(6):339.
Score: 0.321
-
Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015 Jul; 66(1):126-33.
Score: 0.320
-
Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015 Dec; 29(12):705-12.
Score: 0.316
-
Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015 Mar; 22(2):116-22.
Score: 0.315
-
Breaux-Shropshire TL, Whitt L, Griffin RL, Shropshire AT, Calhoun DA. Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. Workplace Health Saf. 2014 Jul; 62(7):292-300.
Score: 0.301
-
Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? Hypertension. 2014 Apr; 63(4):e84.
Score: 0.296
-
Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
Score: 0.295
-
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension. 2014 Mar; 63(3):e17-8.
Score: 0.294
-
Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014 Aug; 28(8):463-8.
Score: 0.292
-
Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014 Mar; 63(3):451-8.
Score: 0.289
-
Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens. 2013 Nov-Dec; 7(6):509-11.
Score: 0.285
-
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
Score: 0.283
-
Pimenta E, Calhoun DA. Response. Chest. 2013 Aug; 144(2):720.
Score: 0.282
-
Calhoun DA, Lacourci?re Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013 Aug; 29(8):901-10.
Score: 0.281
-
Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013 Apr; 143(4):978-983.
Score: 0.276
-
Moreno H, Calhoun DA. True resistant hypertension: definition and prevalence. J Hypertens. 2012 Nov; 30(11):2241-2; author reply 2242-2243.
Score: 0.268
-
Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013; 64:233-47.
Score: 0.268
-
Clark D, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012 May; 28(3):318-25.
Score: 0.258
-
Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012 Apr 03; 125(13):1594-6.
Score: 0.256
-
Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):7-12.
Score: 0.251
-
Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, M?nard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 01; 124(18):1945-55.
Score: 0.249
-
Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011 Sep; 13(9):644-8.
Score: 0.246
-
Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.
Score: 0.244
-
Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2012 May; 26(5):281-7.
Score: 0.243
-
Ahmed MI, Calhoun DA. Resistant hypertension: bad and getting worse. Hypertension. 2011 Jun; 57(6):1045-6.
Score: 0.241
-
Lacourci?re Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011 Oct; 25(10):615-22.
Score: 0.237
-
Ahmed MI, Calhoun DA. Apparent resistant hypertension and medication adherence. Hypertens Res. 2011 Jan; 34(1):41-2.
Score: 0.234
-
Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin. 2010 Nov; 28(4):639-54.
Score: 0.233
-
Pimenta E, Calhoun DA. Treatment of resistant hypertension. J Hypertens. 2010 Nov; 28(11):2194-5.
Score: 0.233
-
Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010 Aug 15; 6(4):363-8.
Score: 0.230
-
Calhoun DA, Harding SM. Sleep and hypertension. Chest. 2010 Aug; 138(2):434-43.
Score: 0.229
-
Calhoun DA. Obstructive sleep apnea and hypertension. Curr Hypertens Rep. 2010 Jun; 12(3):189-95.
Score: 0.227
-
Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010 May; 55(5):1137-42.
Score: 0.224
-
Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. Adv Ther. 2009 Nov; 26(11):1012-23.
Score: 0.220
-
Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug; 24(8):532-7.
Score: 0.220
-
Czarina Acelajado M, Calhoun DA. Treatment of resistant hypertension. Minerva Cardioangiol. 2009 Dec; 57(6):787-812.
Score: 0.219
-
Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009 Nov; 11(6):407-13.
Score: 0.218
-
Ahmed MI, Pisoni R, Calhoun DA. Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2009 Nov; 7(11):1385-93.
Score: 0.218
-
Calhoun DA. Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother. 2009 Aug; 10(12):1869-74.
Score: 0.214
-
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep; 54(3):475-81.
Score: 0.214
-
Acelajado MC, Calhoun DA. Resistant hypertension: who and how to evaluate. Curr Opin Cardiol. 2009 Jul; 24(4):340-4.
Score: 0.213
-
Calhoun DA, Lacourci?re Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 Jul; 54(1):32-9.
Score: 0.211
-
Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension. 2009 Apr; 53(4):585-6.
Score: 0.207
-
Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008 Dec; 10(6):496-503.
Score: 0.204
-
Gonzaga CC, Calhoun DA. 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):396-7.
Score: 0.199
-
Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008 Aug; 24(8):2303-11.
Score: 0.198
-
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24; 117(25):e510-26.
Score: 0.198
-
Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008 Jun 09; 168(11):1159-64.
Score: 0.198
-
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 Jun; 51(6):1403-19.
Score: 0.195
-
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008 Feb; 51(2):339-44.
Score: 0.191
-
Ahmed A, Calhoun D. High blood pressure in older adults: a conversation with Dr David Calhoun. Am J Geriatr Cardiol. 2007 Nov-Dec; 16(6):391-2.
Score: 0.190
-
Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007 Nov; 9(5):353-9.
Score: 0.190
-
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007 Oct; 25(10):2131-7.
Score: 0.188
-
Epstein M, Calhoun DA. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep. 2007 Apr; 9(2):98-105.
Score: 0.182
-
Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007 Feb; 131(2):453-9.
Score: 0.180
-
Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):19-24.
Score: 0.179
-
Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006 Sep; 1(5):1039-45.
Score: 0.173
-
Pimenta E, Calhoun DA. Aldosterone, dietary salt, and renal disease. Hypertension. 2006 Aug; 48(2):209-10.
Score: 0.173
-
Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis. 2006 May-Jun; 48(6):387-96.
Score: 0.171
-
Gaddam KK, Pratt-Ubunama MN, Calhoun DA. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2006 May; 4(3):353-9.
Score: 0.171
-
Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006 Mar; 8(3):181-6.
Score: 0.169
-
Nishizaka MK, Calhoun DA. The role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep. 2005 Oct; 7(5):343-7.
Score: 0.164
-
Pratt-Ubunama MN, Nishizaka MK, Calhoun DA. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep. 2005 Jun; 7(3):186-92.
Score: 0.160
-
Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005 Jun; 18(6):805-12.
Score: 0.160
-
Calhoun DA, Grassi G. Weight gain and hypertension: the chicken-egg question revisited. J Hypertens. 2004 Oct; 22(10):1869-71.
Score: 0.153
-
Nishizaka MK, Calhoun DA. Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):458-60.
Score: 0.151
-
Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004 Jun 15; 109(23):2857-61.
Score: 0.150
-
Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004 Mar; 43(3):518-24.
Score: 0.146
-
Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004 Jan; 125(1):112-7.
Score: 0.145
-
Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003 Nov 04; 139(9):761-76.
Score: 0.144
-
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
Score: 0.144
-
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec; 40(6):892-6.
Score: 0.135
-
Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):221-8.
Score: 0.130
-
Matanes F, Khan MB, Siddiqui M, Dudenbostel T, Calhoun D, Oparil S. An Update on Refractory Hypertension. Curr Hypertens Rep. 2022 07; 24(7):225-234.
Score: 0.129
-
Butts B, Brown JA, Denney TS, Ballinger S, Lloyd SG, Oparil S, Sanders P, Merriman TR, Gaffo A, Singh J, Kelley EE, Calhoun DA, Dell'Italia LJ. Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. Hypertension. 2022 04; 79(4):775-784.
Score: 0.128
-
Aryal SR, Siddiqui M, Sharifov OF, Coffin MD, Zhang B, Gaddam KK, Gupta H, Denney TS, Dell'Italia LJ, Oparil S, Calhoun DA, Lloyd SG. Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. J Am Heart Assoc. 2021 09 07; 10(17):e019434.
Score: 0.124
-
Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, Feig DI, Redden DT, Muntner P, Foster PJ, Biggers-Clark SR, Mudano A, Sattui SE, Saddekni MB, Bridges SL, Saag KG. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis Rheumatol. 2021 08; 73(8):1514-1522.
Score: 0.122
-
Santillan MK, Becker RC, Calhoun DA, Cowley AW, Flynn JT, Grobe JL, Kotchen TA, Lackland DT, Leslie KK, Liang M, Mattson DL, Meyers KE, Mitsnefes MM, Muntner PM, Pierce GL, Pollock JS, Sigmund CD, Thomas SJ, Urbina EM, Kidambi S. Team Science: American Heart Association's Hypertension Strategically Focused Research Network Experience. Hypertension. 2021 06; 77(6):1857-1866.
Score: 0.121
-
Cai A, Liu L, Siddiqui M, Zhou D, Chen J, Calhoun DA, Tang S, Zhou Y, Feng Y. Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes. Am J Hypertens. 2021 02 18; 34(1):64-72.
Score: 0.119
-
Thomas SJ, Johnson DA, Guo N, Abdalla M, Booth JN, Spruill TM, Jackson CL, Yano Y, Sims M, Calhoun D, Muntner P, Redline S. Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens. 2020 10 21; 33(10):949-957.
Score: 0.116
-
Langford AT, Akinyelure OP, Moore TL, Howard G, Min YI, Hillegass WB, Bress AP, Tajeu GS, Butler M, Jaeger BC, Yano Y, Shimbo D, Ogedegbe G, Calhoun D, Booth JN, Muntner P. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. Hypertension. 2020 11; 76(5):1600-1607.
Score: 0.116
-
An J, Sim JJ, Calhoun DA, Liu R, Wei R, Zhou H, Luong T, Reynolds K. Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system. J Hypertens. 2020 08; 38(8):1603-1611.
Score: 0.115
-
Siddiqui M, Dominiczak AF, Touyz RM, Carey RM, Basile J, Heslin MJ, Winokur T, Calhoun DA, Oparil S, Dudenbostel T. Case of Episodic and Positional Hypertension: Diagnosis and Treatment. Hypertension. 2020 09; 76(3):614-621.
Score: 0.114
-
Kwon Y, Stafford PL, Lim DC, Park S, Kim SH, Berry RB, Calhoun DA. Blood pressure monitoring in sleep: time to wake up. Blood Press Monit. 2020 Apr; 25(2):61-68.
Score: 0.112
-
Thomas SJ, Booth JN, Jaeger BC, Hubbard D, Sakhuja S, Abdalla M, Lloyd-Jones DM, Buysse DJ, Lewis CE, Shikany JM, Schwartz JE, Shimbo D, Calhoun D, Muntner P, Carnethon MR. Association of Sleep Characteristics With Nocturnal Hypertension and Nondipping Blood Pressure in the CARDIA Study. J Am Heart Assoc. 2020 04 07; 9(7):e015062.
Score: 0.112
-
Sharman JE, O'Brien E, Alpert B, Schutte AE, Delles C, Hecht Olsen M, Asmar R, Atkins N, Barbosa E, Calhoun D, Campbell NRC, Chalmers J, Benjamin I, Jennings G, Laurent S, Boutouyrie P, Lopez-Jaramillo P, McManus RJ, Mihailidou AS, Ordunez P, Padwal R, Palatini P, Parati G, Poulter N, Rakotz MK, Rosendorff C, Saladini F, Scuteri A, Sebba Barroso W, Cho MC, Sung KC, Townsend RR, Wang JG, Willum Hansen T, Wozniak G, Stergiou G. Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. J Hypertens. 2020 01; 38(1):21-29.
Score: 0.110
-
Alper AB, Calhoun DA. Contemporary management of refractory hypertension. Curr Hypertens Rep. 1999 Oct; 1(5):402-7.
Score: 0.108
-
Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019 09; 37(9):1797-1804.
Score: 0.108
-
Grassi G, Calhoun DA, Mancia G, Carey RM. Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines. Curr Hypertens Rep. 2019 07 18; 21(9):67.
Score: 0.107
-
Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Cambriles TD, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Olmos LF, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. Hypertens Res. 2019 11; 42(11):1708-1715.
Score: 0.106
-
Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Diaz Cambriles T, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Feced Olmos L, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019 06; 37(6):1269-1275.
Score: 0.106
-
Johnson DA, Thomas SJ, Abdalla M, Guo N, Yano Y, Rueschman M, Tanner RM, Mittleman MA, Calhoun DA, Wilson JG, Muntner P, Redline S. Association Between Sleep Apnea and Blood Pressure Control Among Blacks. Circulation. 2019 03 05; 139(10):1275-1284.
Score: 0.104
-
Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019 02; 73(2):424-431.
Score: 0.103
-
Butts B, Calhoun DA, Denney TS, Lloyd SG, Gupta H, Gaddam KK, Aban I, Oparil S, Sanders PW, Patel R, Collawn JF, Dell'Italia LJ. Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. Free Radic Biol Med. 2019 04; 134:343-349.
Score: 0.103
-
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
Score: 0.102
-
Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med. 2018 12; 131(12):1463-1472.e7.
Score: 0.100
-
Thomas SJ, Booth JN, Dai C, Li X, Allen N, Calhoun D, Carson AP, Gidding S, Lewis CE, Shikany JM, Shimbo D, Sidney S, Muntner P. Cumulative Incidence of Hypertension by 55?Years of Age in Blacks and Whites: The CARDIA Study. J Am Heart Assoc. 2018 07 11; 7(14).
Score: 0.099
-
Calhoun DA. Fluid retention, aldosterone excess, and treatment of resistant hypertension. Lancet Diabetes Endocrinol. 2018 06; 6(6):431-433.
Score: 0.098
-
Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician. 1998 Mar 01; 57(5):1007-14, 1019-20.
Score: 0.097
-
Irvin MR, Booth JN, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P. The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018 03; 20(3):438-446.
Score: 0.097
-
Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Hypertens. 2018 01 12; 31(2):133-135.
Score: 0.096
-
Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
Score: 0.095
-
Calhoun DA, Mutinga ML. Race, family history of hypertension, and sympathetic response to cold pressor testing. Blood Press. 1997 Jul; 6(4):209-13.
Score: 0.093
-
Calhoun DA, Oparil S. High blood pressure in women. Int J Fertil Womens Med. 1997 May-Jun; 42(3):198-205.
Score: 0.092
-
Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
Score: 0.091
-
Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017 Apr; 186:29-39.
Score: 0.090
-
Ghazi L, Dudenbostel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Oparil S, Calhoun DA, Rice M, Hage FG. Assessment of vascular function in low socioeconomic status preschool children: a pilot study. J Am Soc Hypertens. 2017 02; 11(2):101-109.
Score: 0.089
-
Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. Am J Med. 2017 Apr; 130(4):439-448.e9.
Score: 0.088
-
Bhatt H, Ghazi L, Calhoun D, Oparil S. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out? Curr Cardiol Rep. 2016 10; 18(10):98.
Score: 0.088
-
Bhandari SK, Shi J, Molnar MZ, Rasgon SA, Derose SF, Kovesdy CP, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ. Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. Respirology. 2016 11; 21(8):1486-1492.
Score: 0.087
-
Schiffrin EL, Calhoun DA, Flack JM. Do We Need a New Definition of Hypertension After SPRINT? Am J Hypertens. 2016 10; 29(10):1127-9.
Score: 0.086
-
Corr?a NB, de Faria AP, Ritter AM, Sabbatini AR, Almeida A, Brunelli V, Calhoun DA, Moreno H, Modolo R. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens. 2016 06; 10(6):510-516.e1.
Score: 0.085
-
Muntner P, Becker RC, Calhoun D, Chen D, Cowley AW, Flynn JT, Grobe JL, Kidambi S, Kotchen TA, Lackland DT, Leslie KK, Li Y, Liang M, Lloyd A, Mattson DL, Mendizabal B, Mitsnefes M, Nair A, Pierce GL, Pollock JS, Safford MM, Santillan MK, Sigmund CD, Thomas SJ, Urbina EM. Introduction to the American Heart Association's Hypertension Strategically Focused Research Network. Hypertension. 2016 Apr; 67(4):674-80.
Score: 0.084
-
Zhu ST, Chen YF, Wyss JM, Nakao K, Imura H, Oparil S, Calhoun DA. Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. Hypertension. 1996 Feb; 27(2):297-302.
Score: 0.084
-
Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC. A Message From the New Editorial Team at the American Journal of Hypertension. Am J Hypertens. 2016 Jan; 29(1):1.
Score: 0.083
-
Calhoun DA, Oparil S. Racial differences in the pathogenesis of hypertension. Am J Med Sci. 1995 Dec; 310 Suppl 1:S86-90.
Score: 0.083
-
Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. Am J Hypertens. 2016 Jan; 29(1):2-4.
Score: 0.083
-
Calhoun DA, Zhu ST, Chen YF, Oparil S. Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 1995 Aug; 26(2):285-9.
Score: 0.081
-
Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
Score: 0.080
-
Calhoun DA, Oparil S. Hypertensive crisis since FDR--a partial victory. N Engl J Med. 1995 Apr 13; 332(15):1029-30.
Score: 0.079
-
Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, Oparil S, Muntner P. Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. Am J Med. 2015 Jul; 128(7):707-14.e2.
Score: 0.079
-
Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, Yano Y, Viera AJ, Shimbo D. Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Hypertens. 2015 May; 28(5):640-8.
Score: 0.077
-
Calhoun DA, Mutinga ML, Wyss JM, Oparil S. Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects. J Hypertens. 1994 Nov; 12(11):1291-6.
Score: 0.077
-
Schiros CG, Desai RV, Venkatesh BA, Gaddam KK, Agarwal S, Lloyd SG, Calhoun DA, Denney TS, Dell'italia LJ, Gupta H. Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson. 2014 Sep 26; 16:70.
Score: 0.076
-
Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015 Apr; 29(4):241-6.
Score: 0.076
-
Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov; 8(11):808-19.
Score: 0.076
-
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
Score: 0.076
-
Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H. Predictors of silent myocardial ischemia in resistant hypertensive patients. Am J Hypertens. 2015 Feb; 28(2):200-7.
Score: 0.076
-
White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
Score: 0.075
-
Calhoun DA, Zhu S, Wyss JM, Oparil S. Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats. Hypertension. 1994 Jul; 24(1):1-7.
Score: 0.075
-
Diaz KM, Booth JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014 Sep; 64(3):465-71.
Score: 0.075
-
de la Sierra A, Calhoun DA, Vinyoles E, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Ruilope LM. Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. J Hum Hypertens. 2014 Jul; 28(7):416-20.
Score: 0.073
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
Score: 0.073
-
Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.
Score: 0.073
-
Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014 Feb; 70(2):147-54.
Score: 0.072
-
Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, Kalantar-Zadeh K, Jacobsen SJ. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013 Oct; 88(10):1099-107.
Score: 0.071
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1583-90.
Score: 0.070
-
Eirin A, Zhu XY, Woollard JR, Herrmann SM, Gloviczki ML, Saad A, Juncos LA, Calhoun DA, Rule AD, Lerman A, Textor SC, Lerman LO. Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension. 2013 Sep; 62(3):585-91.
Score: 0.070
-
Shimbo D, Levitan EB, Booth JN, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013 Feb; 31(2):370-6.
Score: 0.068
-
Calhoun DA. Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. Am J Med Sci. 1992 Nov; 304(5):306-11.
Score: 0.067
-
Gorelick PB, Nyenhuis D, Materson BJ, Calhoun DA, Elliott WJ, Phillips RA, Taler SJ, Townsend RR. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012 Sep-Oct; 6(5):309-15.
Score: 0.066
-
Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2012 Oct; 14(10):694-700.
Score: 0.066
-
Alessi A, Brand?o AA, Coca A, Cordeiro AC, Cordeiro A, Nogueira AR, Di?genes de Magalh?es F, Feitosa A, Amodeo C, Saad Rodrigues CI, Rodrigues C, Calhoun DA, Calhoun D, Barbosa Coelho E, Barbosa E, Pimenta E, Muxfeldt E, Consolin-Colombo FM, Consolin-Colombo F, Salles G, Rosito G, Moreno H, Martin JF, Yugar JC, Aparecido Bortolotto L, Bortolotto L, Naz?rio Scala LC, Scala LC, Gon?alves de Sousa M, Souza Md, Gomes MA, Malachias MB, Gus M, Passarelli O, Jardim PC, Toscano PR, S?nchez RA, Sanchez R, Dischinger Miranda R, Miranda RD, P?voa R, Barroso WK. First Brazilian position on resistant hypertension. Arq Bras Cardiol. 2012 Jul; 99(1):576-85.
Score: 0.065
-
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
Score: 0.064
-
Ahmed MI, Desai RV, Gaddam KK, Venkatesh BA, Agarwal S, Inusah S, Lloyd SG, Denney TS, Calhoun D, Dell'italia LJ, Gupta H. Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging. 2012 Mar; 5(3):273-81.
Score: 0.064
-
Clark D, Guichard JL, Calhoun DA, Ahmed MI. Recent advancements in the treatment of resistant hypertension. Postgrad Med. 2012 Jan; 124(1):67-73.
Score: 0.063
-
Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012 Feb; 59(2):229-37.
Score: 0.063
-
Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens. 2012 Jan-Feb; 6(1):66-72.
Score: 0.062
-
Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011 Aug; 29(8):1553-9.
Score: 0.061
-
Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011 Nov; 25(11):656-64.
Score: 0.060
-
Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, J?nior HM. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011 Aug; 30(8):555-64.
Score: 0.060
-
Calhoun DA, Wyss JM, Oparil S. High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats. Hypertension. 1991 Mar; 17(3):363-8.
Score: 0.060
-
Levine DA, Calhoun DA, Prineas RJ, Cushman M, Howard VJ, Howard G. Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens. 2011 Apr; 24(4):482-8.
Score: 0.059
-
Levine DA, Lewis CE, Williams OD, Safford MM, Liu K, Calhoun DA, Kim Y, Jacobs DR, Kiefe CI. Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension. 2011 Jan; 57(1):39-47.
Score: 0.059
-
Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med. 1990 Oct 25; 323(17):1177-83.
Score: 0.058
-
Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011 Sep; 25(9):532-8.
Score: 0.058
-
Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010 Aug; 28(3):517-27.
Score: 0.057
-
Zappe DH, Palmer BF, Calhoun DA, Purkayastha D, Samuel R, Jamerson KA. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. J Hum Hypertens. 2010 Jul; 24(7):483-91.
Score: 0.055
-
Acelajado MC, Calhoun DA, Oparil S. Reduction of blood pressure in patients with treatment-resistant hypertension. Expert Opin Pharmacother. 2009 Dec; 10(18):2959-71.
Score: 0.055
-
Feng W, Nagaraj H, Gupta H, Lloyd SG, Aban I, Perry GJ, Calhoun DA, Dell'Italia LJ, Denney TS. A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR. J Cardiovasc Magn Reson. 2009 Aug 13; 11:30.
Score: 0.054
-
Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009 Mar-Apr; 51(5):371-80.
Score: 0.052
-
Oparil S, Calhoun DA. Hypertension. Dis Mon. 1989 Mar; 35(3):133-232.
Score: 0.052
-
Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol. 2009 Feb; 34(2):51-84.
Score: 0.052
-
Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul; 23(7):479-89.
Score: 0.052
-
Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
Score: 0.050
-
White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008 Jun; 10(6):450-8.
Score: 0.049
-
Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension. 2007 Sep; 50(3):447-53; discussion 447-53.
Score: 0.047
-
Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007 Jun; 88(6):683-92.
Score: 0.046
-
Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan; 25(1):217-26.
Score: 0.045
-
Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006 Dec 12; 114(24):2572-4.
Score: 0.045
-
Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol. 2001 Nov; 281(5):C1413-21.
Score: 0.031
-
Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001 Aug; 23(8):1166-79.
Score: 0.031
-
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020 07 07; 173(1):10-20.
Score: 0.028
-
Fang Z, Sripairojthikoon W, Calhoun DA, Zhu S, Berecek KH, Wyss JM. Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens. 1999 Jul; 17(7):983-91.
Score: 0.027
-
Guichard JL, Clark D, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag. 2013; 9:321-31.
Score: 0.018
-
Grassi G, Seravalle G, Calhoun DA, Matturri M, Mancia G, Zanchetti A. Monitoring of sympathetic activity in man: physiology and pharmacology. Eur Heart J. 1992 Jun; 13 Suppl A:22-5.
Score: 0.016
-
Grassi G, Seravalle G, Calhoun D, Bolla GB, Mancia G. Physical exercise in essential hypertension. Chest. 1992 May; 101(5 Suppl):312S-314S.
Score: 0.016
-
Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
Score: 0.010